Neoantigen vaccines are at the forefront of cancer research, driving personalized immunotherapy and improving outcomes ...
Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma December 11, 2025 9:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback